cmi_logo.png
[Latest] Global Bispecific Antibodies Market Size/Share Worth USD 53.8 Billion by 2033 at a 24.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
April 04, 2024 12:30 ET | Custom Market Insights
Austin, TX, USA, April 04, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Bispecific Antibodies Market Size, Trends and Insights By Application (Cancer...
Dyadic Logo Current.jpg
Dyadic to Attend Industry Events in March
March 01, 2024 08:30 ET | Dyadic International, Inc.
JUPITER, Fla. , March 01, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic Logo Current.jpg
Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions
February 21, 2024 08:30 ET | Dyadic International, Inc.
JUPITER, Fla. and NES-ZIONA, Israel, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company specializing in advanced...
Dyadic Logo Current.jpg
Dyadic to Attend BIO CEO & Investor Conference and European Industry Events
February 01, 2024 08:30 ET | Dyadic International, Inc.
JUPITER, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic Logo Current.jpg
Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference
January 02, 2024 08:30 ET | Dyadic International, Inc.
JUPITER, Fla., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic Logo Current.jpg
Dyadic to Present at BioProcess International
September 12, 2023 16:30 ET | Dyadic International, Inc.
JUPITER, Fla., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
TIP_link_300x300.jpg
Immunohistochemistry Market worth $3.58 Billion by 2028 - Exclusive Report by The Insight Partners
August 29, 2023 07:48 ET | The Insight Partners
Pune, India, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Immunohistochemistry is a tool used microscopy-based techniques to observe cellular components such as proteins or other macromolecules in a tissue...
Dyadic Logo Current.jpg
Dyadic Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
August 09, 2023 16:00 ET | Dyadic International, Inc.
Positive Interim Phase 1 clinical trial safety results for C1 platform for manufacturing human vaccines Two MoU’s with Fondazione Biotecnopolo di Siena in Italy and Essential Drugs Company Limited...
Dyadic Logo Current.jpg
Dyadic to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
July 26, 2023 16:30 ET | Dyadic International, Inc.
JUPITER, Fla., July 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Dyadic Logo Current.jpg
Dyadic Announced an MoU with Bangladesh’s State-Owned Pharmaceutical Company to Facilitate Biopharmaceutical Research and Biomanufacturing Capacity
June 21, 2023 08:33 ET | Dyadic International, Inc.
JUPITER, Fla. and DHAKA, Bangladesh, June 21, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company...